Study record managers: refer to the Data Element Definitions if submitting registration or results information. NNC will be administered subcutaneously s. Active Comparator: Faster aspart Participants randomised to faster aspart. Drug: Fast-acting insulin aspart Participants will get a fixed dose of 0.
Navigation menu
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general Why Type I Diabetes Mellitus, Learn About Clinical Studies.
Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms x. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Diabrtes.
Subjects and Methodology
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Last Update Posted : December 7, See Contacts and Locations. Study Description.
Introduction
This study is looking at the safety of the new medicine, insulin Why Type I Diabetes Mellitus, its concentrations in the blood and effect on blood sugar for the treatment of type 1 diabetes. Insulin NNC will be compared to faster aspart. The purpose of this study is Melitus test how insulin NNC is tolerated by participants body, how it is transported in participants bloodstream, how long it stays there and how the blood sugar is lowered compared to faster aspart. Participants will get either the new insulin NNC or faster aspart-which treatment participants get is decided by chance.
It is the first time insulin NNC is tested in people. Faster aspart is a globally used medication for treatment of diabetes mellitus. Participants will click at this page one single injection in a fasting state which will take place at the study site. The medicine will be injected under the skin in the stomach. The study will last for about days, depending on individual visit schedule. Participants will have four clinic visits with the study doctor, one of which will require an in-house visit period of 3 days. During the in-house visit, two intravenous cannulas will be inserted for sampling of blood and infusion of insulin. Participants cannot be Why Type I Diabetes Mellitus the study if the study Diabetrs thinks that there are risks to their health.]
You have hit the mark.
I apologise, but, in my opinion, you are mistaken. Let's discuss it.